Abstract:Pituitary adenylate cyclase activating polypeptide (PACAP), vasoactive intestinal peptide (VIP) and peptide histidine-isoleucine (PHI), are structurally related endogenous peptides widely expressed in the central and peripheral nervous system and showing rich profile of biological activities. They act as neurotransmitters, neuromodulators and neurotrophic factors. Recently, their neuroprotective potential has been revealed in numerous in vitro and in vivo models. Thus, PACAP and VIP protected the cells from neurotoxic effects of ethanol, hydrogen peroxide (H2O2, beta-amyloid and glycoprotein 120 (gp120). Moreover, PACAP showed neuroprotection against glutamate, human prion protein fragment 106-126 [PrP(106-126)] and C2-ceramide. Both peptides reduced brain damage after ischemia and ameliorated neurological deficits in a model of Parkinson's disease. Neuroprotective potential of PHI has not been thoroughly investigated yet, but several results obtained in the last years do not exclude it. The mechanism underlying neuroprotective properties of PACAP seems to involve activation of adenylyl cyclase (AC) --> cyclic adenosine 3',5'-mono-phosphate (cAMP) --> protein kinase A (PKA) and mitogen-activated protein (MAP) kinase pathways, and inhibition of caspase-3. PACAP can also, yet indirectly, stimulate astrocytes to release neuroprotective factors, such as regulated upon activation normal T cell expressed and secreted (RANTES) and macrophage inflammatory protein 1 (MIP-1) chemokines. Neuroprotective activity of VIP seems to involve an indirect mechanism requiring astrocytes. VIP-stimulated astrocytes secrete neuroprotective proteins, including activity-dependent neurotrophic factor (ADNF) and activity-dependent neuroprotective protein (ADNP), as well as a number of cytokines. However, in the activated microglia, VIP and PACAP are capable of inhibiting the production of inflammatory mediators which can lead to neurodegenerative processes within the brain. In conclusion, studies carried out on the central nervous system have shown that PACAP, VIP, and likely PHI, are endowed with a neuroprotective potential, which renders them (or their derivatives) promising therapeutic agents in several psychoneurological disorders linked to neurodegeneration.

TAT-tagging of VIP exerts positive allosteric modulation of the PAC1 receptor and enhances VIP neuroprotective effect in the MPTP mouse model of Parkinson's disease

Novel Peptide VIP-TAT with Higher Affinity for PAC1 Inhibited Scopolamine Induced Amnesia

Retinoprotective Effects of TAT-Bound Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase Activating Polypeptide

The TAT Peptide Endows PACAP with an Enhanced Ability to Traverse Bio-Barriers

Positive allosteric regulation of PAC1-R up-regulates PAC1-R and its specific ligand PACAP

Therapeutic Effect of Neuropeptide PACAP27 on Parkinson's Disease in Mice

Positive Allosteric Regulation of PAC1-R Up-Regulates&lt;?a3b2 ACK?&gt;PAC1-R and Its Specific Ligand PACAP

Positive allosteric regulation of PAC1-R up-regulates<?A3B2 ACK?>PAC1-R and its specific ligand PACAP

Neuroprotective Effects of Pacap27 in Mice Model of Parkinson'S Disease Involved in the Modulation of K(Atp) Subunits and D2 Receptors in the Striatum

A novel small positive allosteric modulator of neuropeptide receptor PAC1-R exerts neuroprotective effects in MPTP mouse Parkinson's disease model

A Novel Small Positive Allosteric Modulator of Neuropeptide Receptor PAC1-R Exerts Neuroprotective Effects in MPTP Mouse Parkinson’s Disease Model

The Palmitoylation of the N-terminal Extracellular Cys37 Mediates the Nuclear Translocation of VPAC1 Contributing to Its Anti-Apoptotic Activity.

Vip Enhances Phagocytosis Of Fibrillar Beta-Amyloid By Microglia And Attenuates Amyloid Deposition In The Brain Of App/Ps1 Mice

Vasoactive Intestinal Peptide Attenuates Liver Ischemia/reperfusion Injury in Mice Via the Cyclic Adenosine Monophosphate-Protein Kinase a Pathway.

Understanding VPAC receptor family peptide binding and selectivity

Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors

A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease

Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases

Neuroprotective potential of three neuropeptides PACAP, VIP and PHI

EXPERIMENTAL STUDY OF PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE ON RELIEVING BRAIN EDEMA INDUCED BY ISCHEMIA IN RATS

Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC1 receptor